CVR number 28490704
Industry 46.4610 Wholesale of pharmaceutical goods

KEBOMED A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  0.7% 1.2% 1.1% 3.8% 2.4%  
Credit score (0-100)  96 81 84 50 63  
Credit rating  AA A A BBB BBB  
Credit limit (kDKK)  2,993.4 1,007.6 2,869.3 0.0 0.9  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  38,994 41,485 39,409 41,324 42,647  
EBITDA  11,573 16,757 11,699 12,142 11,523  
EBIT  11,573 16,757 11,699 12,142 11,523  
Pre-tax profit (PTP)  11,596.6 16,573.1 11,677.5 12,298.7 11,880.2  
Net earnings  9,022.2 12,906.6 9,092.6 9,544.0 9,233.5  
Pre-tax profit without non-rec. items  11,597 16,573 11,677 12,299 11,880  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  39.0 15.1 2.4 0.0 0.0  
Shareholders equity total  18,338 31,244 40,337 49,881 59,114  
Interest-bearing liabilities  7,304 230 6,659 7,742 12,613  
Balance sheet total (assets)  38,682 43,223 53,362 62,975 87,133  
Net Debt  5,263 -6,595 -12,156 -10,011 -17,112  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  38,994 41,485 39,409 41,324 42,647  
Gross profit growth  3.3% 6.4% -5.0% 4.9% 3.2%  
Employees  27 0 23 22 22  
Employee growth %  0.0% -100.0% 0.0% -4.3% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  38,682 43,223 53,362 62,975 87,133  
Balance sheet change%  -18.7% 11.7% 23.5% 18.0% 38.4%  
Added value  11,573.4 16,757.3 11,698.5 12,142.1 11,522.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -24 -24 -13 -2 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  29.7% 40.4% 29.7% 29.4% 27.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  27.3% 40.9% 24.6% 21.6% 16.9%  
ROI %  41.5% 56.2% 29.3% 23.7% 19.6%  
ROE %  65.3% 52.1% 25.4% 21.2% 16.9%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  47.4% 72.3% 75.6% 79.2% 67.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  45.5% -39.4% -103.9% -82.4% -148.5%  
Gearing %  39.8% 0.7% 16.5% 15.5% 21.3%  
Net interest  0 0 0 0 0  
Financing costs %  1.3% 5.2% 5.6% 3.5% 7.7%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  1.0 3.1 3.2 3.6 2.2  
Current Ratio  2.2 5.2 5.1 5.7 3.4  
Cash and cash equivalent  2,041.0 6,824.7 18,814.6 17,753.0 29,724.9  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  20,837.0 34,808.6 42,762.1 51,926.1 61,761.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  429 0 509 552 524  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  429 0 509 552 524  
EBIT / employee  429 0 509 552 524  
Net earnings / employee  334 0 395 434 420